All In Biotech

Drug Trial Radar · NCT04910776

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa

An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naïve Pediatric Participants With Infantile-Onset Pompe Disease (IOPD)

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

17

Actual

Start

Sep 1, 2021

Primary completion

Mar 2, 2026

Study completion Aug 10, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 days, up to 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single group, treatment, Phase 3, open-label study to assess efficacy, safety, pharmacokinetic (PK), pharmacodynamics (PD) of avalglucosidase alfa in treatment-naïve male and female participants with IOPD. Study details include: * Study duration: Screening - up to 4 weeks; * Primary Analysis Period (PAP) - 52 weeks; * Extended Treatment Period (ETP) - 52 weeks; * Extended Long term Treatment Period (ELTP) - 104 weeks; 4-week follow-up period for a total study duration - up to 4.08 years. * Treatment duration: Up to 4 years * Visit frequency: every other week and potentially every week

Conditions

  • Glycogen Storage Disease Type II

Interventions

  • avalglucosidase alfaDrug

    Sterile lyophilized powder intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who are alive and free of invasive ventilation at Week 52Time frame: Week 52

Locations

16 sites in 9 countries. Site status is shown where the registry gives one.

  • Stanford Hospital- Site Number : 8400006

    Stanford, California

  • Children's Hospitals and Clinics of Minnesota- Site Number : 8400008

    Minneapolis, Minnesota

  • Advanced Medical Genetics- Site Number : 8400002

    Hawthorne, New York

  • Duke University Medical Center- Site Number : 8400004

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center- Site Number : 8400001

    Cincinnati, Ohio

  • Seattle Children's Hospital- Site Number : 8400003

    Seattle, Washington

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • Investigational Site Number : 1560002

    Qingdao, China

  • Investigational Site Number : 1560001

    Shanghai, China

  • Investigational Site Number : 2760001

    Bad Oeynhausen, Germany

  • Investigational Site Number : 3800002

    Monza, Lombardy, Italy

  • Investigational Site Number : 5280001

    Rotterdam, Netherlands

  • Investigational Site Number : 7240001

    Esplugues de Llobregat, Catalunya [Cataluña], Spain

  • Investigational Site Number : 1580001

    Taipei, Taiwan

  • Investigational Site Number : 8260002

    Manchester, United Kingdom

  • Investigational Site Number : 8260001

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.